Long-term Outlook and Future Research Conclusion Semaglutide offers promising benefits for weight management, but its essential to consider its potential effects on menstrual health
Tirzepatide MTD had the highest likelihood of being the most effective treatment for waist circumference reduction (SUCRA=0.93), followed by tirzepatide 15 mg (SUCRA=0.88) and tirzepatide 10 mg (SUCRA=0.64)
Start your medical weight loss consultation with Slinic to begin your transformation with quiet confidence
Not all biomarkers changed, as AdaptAge, CausAge, and DamAge exhibited small, heterogeneous, non-significant shifts, and the Intrinsic Capacity (IC) clock, linked to physical and cognitive resilience, did not differ between groups (estimated group difference: 0.003 IC score
Daniel Skovronsky, Eli Lilly's chief scientific officer and president of Lilly Research Labs
The results aim to inform clinical practice and guideline development, offering insights into optimal pharmacologic choices for obesity management